Cell plasticity in cancer and therapy resistance
- 1Department of Experimental Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA
- 2Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX USA
- 3Program in Genetics and Epigenetics, The University of Texas MD Anderson Cancer Center, Houston, TX USA
Abstract
Cancer cell plasticity, the ability of tumor cells to switch between distinct cellular states, has emerged as a key mechanism driving tumor progression, metastasis and therapy resistance. Cancer cells exploit diverse plasticity mechanisms, including dedifferentiation, transdifferentiation, epithelial–mesenchymal transition and stem cell-like reprogramming, to adapt to changes in their microenvironment or therapeutic pressures. These transitions are orchestrated by signaling pathways, epigenetic modifications and microenvironmental cues. Notably, plasticity encompasses reversible transitions among intermediate states that enhance metastatic potential and contribute to therapeutic failure. Tumor cells can enter drug-tolerant reversible states, enabling survival during treatment and leading to relapse. Recent advances in single-cell and spatial transcriptomics, along with conceptual frameworks such as the Waddington landscape, have provided new insights into the dynamic regulation of tumor cell-state transitions at high resolution. In this Review, we discuss the molecular and cellular mechanisms governing cancer cell plasticity, its impact on metastasis and therapy resistance, and recent technological advances that illuminate dynamic tumor cell-state transitions.
Related
- Epigenetic and RNA control of cancer stem cell plasticity and therapy resistance
- FOXM1 as a candidate dosage rheostat and state selector in breast cancer: linking multilevel regulation to adaptive plasticity and therapy resistance
- Cellular senescence in ovarian cancer: a proposed geroncogenic shift linking aging, plasticity, and therapy resistance
- Shining a Light on the Mechanisms of Drug Resistance to Anti-PD-1 Therapy in Non-small Cell Lung Cancer.
- Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy
BibTeX
@article{seo2026cell,
title = {{Cell plasticity in cancer and therapy resistance}},
author = {Yoojeong Seo and Jinho Jang and Jae-Il Park},
journal = {Experimental \& Molecular Medicine},
year = {2026},
month = oct,
doi = {10.1038/s12276-026-01869-y},
url = {https://doi.org/10.1038/s12276-026-01869-y},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cell plasticity in cancer and therapy resistance
AU - Yoojeong Seo
AU - Jinho Jang
AU - Jae-Il Park
PY - 2026
DA - 2026/10/07
JO - Experimental & Molecular Medicine
DO - 10.1038/s12276-026-01869-y
UR - https://doi.org/10.1038/s12276-026-01869-y
AB - Cancer cell plasticity, the ability of tumor cells to switch between distinct cellular states, has emerged as a key mechanism driving tumor progression, metastasis and therapy resistance. Cancer cells exploit diverse plasticity mechanisms, including dedifferentiation, transdifferentiation, epithelial–mesenchymal transition and stem cell-like reprogramming, to adapt to changes in their microenvironment or therapeutic pressures. These transitions are orchestrated by signaling pathways, epigenetic modifications and microenvironmental cues. Notably, plasticity encompasses reversible transitions among intermediate states that enhance metastatic potential and contribute to therapeutic failure. Tumor cells can enter drug-tolerant reversible states, enabling survival during treatment and leading to relapse. Recent advances in single-cell and spatial transcriptomics, along with conceptual frameworks such as the Waddington landscape, have provided new insights into the dynamic regulation of tumor cell-state transitions at high resolution. In this Review, we discuss the molecular and cellular mechanisms governing cancer cell plasticity, its impact on metastasis and therapy resistance, and recent technological advances that illuminate dynamic tumor cell-state transitions.
SN - 1226-3613
SN - 2092-6413
ER -